Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

3.00USD
20 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.00
Open
$3.18
Day's High
$3.18
Day's Low
$2.96
Volume
65,818
Avg. Vol
68,247
52-wk High
$17.10
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Amyris Inc enters into agreement with Koninklijke DSM N.V.
Thursday, 5 Oct 2017 08:30am EDT 

Oct 5 (Reuters) - Amyris Inc :Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient.Amyris Inc - ‍entered into a product development and production agreement for a new class of human nutrition ingredients with Koninklijke DSM N.V.​.Amyris Inc - partnership announced is focused on developing ingredient for market introduction in 2019.  Full Article

Amyris enters into second major product development with Royal DSM
Tuesday, 26 Sep 2017 08:30am EDT 

Sept 26 (Reuters) - Amyris Inc :Amyris Inc enters into second major product development and production agreement with Royal DSM.Amyris Inc - ‍has entered into a product development and production agreement for vitamin A with Koninklijke DSM N.V.​.Amyris Inc - DSM is partnering with Amyris to fund development of technology to produce vitamin A​.  Full Article

Amyris Q2 loss per share $0.46
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Amyris Inc :Amyris delivers another strong quarter with revenue of $25.7 million and product sales increase of 159% over 2nd quarter of 2016.Q2 loss per share $0.46.Q2 revenue rose 168 percent to $25.7 million.Says Q2 2017 product sales of $12.7 million, up 159% over $4.9 million for Q2 2016.  Full Article

Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​
Thursday, 3 Aug 2017 08:30am EDT 

Aug 3 (Reuters) - Amyris Inc :Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million.Amyris Inc - ‍second tranche of $50 million in a private placement days is being led by a $25-million investment from Koninklijke DSM N.V.​.Amyris Inc - ‍remaining $25 million of $50 million private placement contributed by Vivo Capital, a healthcare investment firm​.Amyris Inc - ‍following close of tranche, Vivo Capital will be granted an Amyris board seat and DSM gains an additional board seat​.  Full Article

Biossance says will expand to Sephora in over 60 Sephora locations across Canada
Wednesday, 26 Jul 2017 08:30am EDT 

July 26 (Reuters) - Amyris Inc ;:Biossance says will expand to Sephora in over 60 Sephora locations across Canada in January 2018.  Full Article

Amyris enters into first product development, production agreement with Royal DSM
Monday, 17 Jul 2017 08:50am EDT 

July 17 (Reuters) - Amyris Inc ::Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule.Amyris Inc - ‍as part of agreement, DSM will partner with co, fund development of technology to produce specific molecule that co will scale, supply​.  Full Article

Amyris, on June 30, 2017, company issued, sold an amended, restated note in principal amount of $3 mln to purchaser
Friday, 7 Jul 2017 05:05pm EDT 

July 7 (Reuters) - Amyris Inc ::Amyris Inc - on June 30, 2017, company issued and sold an amended and restated note in principal amount of $3.0 million to purchaser - sec filing.Amyris Inc - in connection with issuance and sale of $3 million note, company and purchaser entered into a letter agreement.Amyris Inc - pursuant to letter agreement, purchaser has right to cause coto redeem all of outstanding principal amount of $3 million note in cash.Amyris Inc - pursuant to letter agreement purchaser has right to cause company to redeem all of outstanding principal amount of $3 million note in cash.  Full Article

Amyris and government of Queensland announced plans to develop a industrial biotechnology hub in Southeast Asia
Tuesday, 20 Jun 2017 08:30am EDT 

June 20 (Reuters) - Amyris Inc :Amyris Inc and government of Queensland, Australia announced plans to develop a industrial biotechnology hub in Southeast Asia.  Full Article

Amyris announces reverse stock split
Tuesday, 6 Jun 2017 08:00am EDT 

June 6 (Reuters) - Amyris Inc :Amyris announces reverse stock split - delivering on strong product revenue growth and execution.Amyris Inc- every 15 pre-split shares of common stock held by stockholders will automatically be converted into one share of common stock.Amyris Inc - co's common stock will begin trading on a split-adjusted basis as of commencement of trading on june 6, 2017.  Full Article

Amyris reports Q1 loss per share of $0.13
Monday, 15 May 2017 04:22pm EDT 

May 15 (Reuters) - Amyris Inc :Amyris reports 164 pct product revenue growth over prior year & continued strong outlook.Q1 loss per share $0.13.Q1 revenue rose 47 percent to $13 million.Q1 revenue view $32.3 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S."Expect to deliver around $60 million of product revenue for 2017"."Significant" progress in healthy sweeteners with expected commercial production in 2018 of low cost.Sees FY total revenue to be "better than" 2017 plan.Expects growing farnesene for vitamin E oil from around $6 million in 2016 to around $20 million in 2017.Expect to deliver around $60 million of product revenue for 2017, or more than double from 2016.  Full Article

BRIEF-Amyris Inc enters into agreement with Koninklijke DSM N.V.

* Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient